Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artificial Tears for Cataract Surgery Biometry
NCT04230720Phase 4Withdrawn
- Sponsor
- Weill Cornell Medicine
- Start
- Apr 2021
- Primary completion
- Dec 2021
- Modality
- Nanoparticles, Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 4 trial of propylene glycol-hydroxypropyl guar nanoemulsion in cataract, sponsored by Weill Cornell Medicine. Planned start Apr 2021; status: withdrawn.
02
Drugs
propylene glycol-hydroxypropyl guar nanoemulsion
03
Conditions
cataract
Beyond the preview
Go deeper on NCT04230720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04230720.